Defining the next generation
of CAR T-cell therapy
Verismo Therapeutics is pioneering CAR T-cell therapy for the treatment of solid tumors. This paradigm-shifting technology features a unique KIR-CAR construct that has been proven to reduce T-cell exhaustion and kill solid tumor models in in vivo studies.
The paradigm shift in CAR T-cell therapy
Verismo’s paradigm-shifting generation 2.0 KIR-CAR platform:
- Features multi-chain immunoreceptor design
- Enables T-cells to remain effective long-term
- Excels in challenging solid tumor micro-environments
Prior 1.X CAR T-cell therapies:
- Utilize the traditional single-chain CAR construct
- Fail to eliminate solid tumors
- Exhausts T-cells through constant single-chain stimulation
The first KIR-CAR platform
proven to be effective on
solid tumors
Verismo is pioneering the further development of novel chimeric antigen receptors (CARs) to more realistically reflect the design of killer immunoglobulin-like receptors (KIRs), creating SynKIR™.
Based on NK cell receptors, KIR-CAR naturally overcomes T-cell exhaustion.
The experts behind SynKIR
Verismo was founded by the inventors of Kymriah™. This team saw an opportunity to overcome the limitations found in the first-generation CAR T-cell therapies, through the use of a KIR-CAR platform.
